Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · Real-Time Price · USD
0.3799
-0.0065 (-1.68%)
At close: Nov 17, 2026, 4:00 PM EST
0.3690
-0.0109 (-2.87%)
After-hours: Nov 17, 2026, 5:46 PM EST

Jaguar Health Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
27.0811.5111.699.7611.964.34
Revenue Growth
129.74%-1.52%19.75%-18.36%175.80%-53.81%
Cost of Revenue
5.023.771.962.042.022.33
Gross Profit
22.067.749.737.729.942
Selling, General & Admin
20.7527.8824.0223.0526.7126
Research & Development
25.1924.9716.5418.617.6515.08
Operating Expenses
45.9452.8540.5741.6444.3541.08
Operating Income
-23.88-45.11-30.83-33.92-34.42-39.07
Interest Expense
-1.15-0.07-0.23-6.38-12.72-8.42
Other Non Operating Income (Expenses)
-3.72-6.22-9.43-4.930.93-2.72
EBT Excluding Unusual Items
-28.75-51.4-40.5-45.23-46.21-50.21
Asset Writedown
----0.37--
Other Unusual Items
-3.55-1.81.253.7-2.19-2.39
Pretax Income
-33.1-54-39.25-41.9-48.4-52.6
Earnings From Continuing Operations
-33.1-54-39.25-41.9-48.4-52.6
Minority Interest in Earnings
0.490.560.760.60.940.01
Net Income
-32.61-53.43-38.49-41.3-47.45-52.6
Preferred Dividends & Other Adjustments
16.890.14----
Net Income to Common
-49.49-53.58-38.49-41.3-47.45-52.6
Net Income Growth
------
Shares Outstanding (Basic)
0-----
Shares Outstanding (Diluted)
0-----
Shares Change
------
EPS (Basic)
-169.30-----
EPS (Diluted)
-169.31-----
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-6.91-23.73-29.4-33.24-33.18-34.98
Free Cash Flow Per Share
-23.64-----
Gross Margin
81.47%67.21%83.28%79.13%83.11%46.18%
Operating Margin
-88.20%-391.87%-263.76%-347.50%-287.85%-901.36%
Profit Margin
-182.80%-465.42%-329.30%-423.11%-396.91%-1213.26%
Free Cash Flow Margin
-25.53%-206.12%-251.52%-340.56%-277.53%-806.83%
EBITDA
-21.98-43.2-28.93-31.91-32.43-37.36
EBITDA Margin
-81.20%--247.51%--271.28%-
D&A For EBITDA
1.91.911.92.011.981.72
EBIT
-23.88-45.11-30.83-33.92-34.42-39.07
EBIT Margin
-88.20%--263.76%--287.85%-
Revenue as Reported
27.0811.5111.699.76-4.34
SEC Filings: 10-K · 10-Q